Safety and efficacy of C1-inhibitor in traumatic brain injury (CIAO@TBI): study protocol for a randomized, placebo-controlled, multi-center trial
Abstract Background Traumatic brain injury (TBI) is a major cause of death and disability across all ages. After the primary impact, the pathophysiologic process of secondary brain injury consists of a neuroinflammation response that critically leads to irreversible brain damage in the first days af...
Guardado en:
Autores principales: | Inge A. M. van Erp, Thomas A. van Essen, Kees Fluiter, Erik van Zwet, Peter van Vliet, Frank Baas, Iain Haitsma, Dagmar Verbaan, Bert Coert, Godard C. W. de Ruiter, Wouter A. Moojen, Mathieu van der Jagt, Wilco C. Peul |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b89b282f61b84e6a94a926ddd61fe737 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ciao, Güiyermo, arrivederci!
por: Víctor A. Nava Marín
Publicado: (2012) -
Traumatic Brain Injury and Neuroinflammation: Review of the Main Biomarkers
por: A. I. Zudova, et al.
Publicado: (2020) -
Carnosine quenches the reactive carbonyl acrolein in the central nervous system and attenuates autoimmune neuroinflammation
por: Jan Spaas, et al.
Publicado: (2021) -
Mechanisms Involved in Microglial-Interceded Alzheimer’s Disease and Nanocarrier-Based Treatment Approaches
por: Shadab Md, et al.
Publicado: (2021) -
Depression and chronic pain in the elderly: links and management challenges
por: Zis P, et al.
Publicado: (2017)